Literature DB >> 23197499

Anxiety disorders, physical illnesses, and health care utilization in older male veterans with Parkinson disease and comorbid depression.

Salah U Qureshi1, Amber B Amspoker, Jessica S Calleo, Mark E Kunik, Laura Marsh.   

Abstract

This study examined the rates of anxiety and depressive disorders, physical illnesses, and health service use in male patients 55 years or older with a diagnosis of Parkinson disease who were seen at least twice at the 10 medical centers in the Veterans Affairs Healthcare Network of the South Central region of the United States. Of the 273 male patients diagnosed between October 1, 1997, and September 30, 2009, 62 (22.7%) had a depressive disorder. The overall prevalence of anxiety disorders was 12.8%; patients with comorbid depression had a 5-fold greater prevalence of anxiety disorders than those without depression (35.5% vs 6.2%, P<.0001). Patients with comorbid depression also had increased prevalence of all physical illnesses examined and more outpatient clinic and mental health visits. Patients with Parkinson disease and comorbid depression are more likely to have anxiety disorders and several physical illnesses, to be using antipsychotic and dementia medicines, and to have increased health service utilization than those without depression.

Entities:  

Mesh:

Year:  2012        PMID: 23197499     DOI: 10.1177/0891988712466458

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  14 in total

Review 1.  Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson's disease.

Authors:  Atami Sagna; Joseph J Gallo; Gregory M Pontone
Journal:  Parkinsonism Relat Disord       Date:  2014-04-01       Impact factor: 4.891

2.  [Coexistent depressive and anxiety disorders in neurological diseases: from a perspective of multimorbidity].

Authors:  H P Kapfhammer
Journal:  Nervenarzt       Date:  2014-04       Impact factor: 1.214

Review 3.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  Anna Nagy; Anette Schrag
Journal:  J Neural Transm (Vienna)       Date:  2019-05-29       Impact factor: 3.575

Review 4.  Medication adherence in patients with Parkinson's disease.

Authors:  Naveed Malek; Donald G Grosset
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

Review 5.  Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.

Authors:  Stéphane Prange; Hélène Klinger; Chloé Laurencin; Teodor Danaila; Stéphane Thobois
Journal:  Drugs Aging       Date:  2022-06-16       Impact factor: 4.271

6.  Hospital care for mental health and substance abuse conditions in Parkinson's disease.

Authors:  Allison W Willis; Dylan P Thibault; Peter N Schmidt; E Ray Dorsey; Daniel Weintraub
Journal:  Mov Disord       Date:  2016-12       Impact factor: 10.338

Review 7.  Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease.

Authors:  Edward C Lauterbach
Journal:  Am J Neurodegener Dis       Date:  2016-03-01

8.  Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson's Disease.

Authors:  Danielle S Abraham; Thanh Phuong Pham Nguyen; Sean Hennessy; Shelly L Gray; Dawei Xie; Daniel Weintraub; Allison W Willis
Journal:  Am J Geriatr Psychiatry       Date:  2020-05-18       Impact factor: 4.105

9.  A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson's disease.

Authors:  Lakkhina Troeung; Sarah J Egan; Natalie Gasson
Journal:  BMC Psychiatry       Date:  2014-01-27       Impact factor: 3.630

10.  Anxiety and anxious-depression in Parkinson's disease over a 4-year period: a latent transition analysis.

Authors:  S Landau; V Harris; D J Burn; J V Hindle; C S Hurt; M Samuel; K C Wilson; R G Brown
Journal:  Psychol Med       Date:  2015-10-23       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.